Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2010-02-02
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S218000, C514S248000, C514S249000, C514S263220, C514S573000
Reexamination Certificate
active
07655662
ABSTRACT:
Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
REFERENCES:
patent: 5219849 (1993-06-01), Lotti et al.
patent: 5798380 (1998-08-01), Kaufman et al.
patent: 6110912 (2000-08-01), Kaufman et al.
patent: 6218410 (2001-04-01), Uehata et al.
patent: 6271224 (2001-08-01), Kapin et al.
patent: 6403590 (2002-06-01), Hellberg et al.
patent: 6451825 (2002-09-01), Uehata et al.
patent: 6586425 (2003-07-01), Kaufman et al.
patent: 6649625 (2003-11-01), Azuma et al.
patent: 6673812 (2004-01-01), Azuma et al.
patent: 6720341 (2004-04-01), Moriyama et al.
patent: 6794398 (2004-09-01), Nakamuta et al.
patent: 2002/0045585 (2002-04-01), Kaufman et al.
patent: 2005/0153984 (2005-07-01), Chen et al.
patent: 2005/0197328 (2005-09-01), Bailey et al.
patent: 2006/0142307 (2006-06-01), Hellberg et al.
patent: 1 034 793 (2000-09-01), None
patent: WO 99/23113 (1999-05-01), None
patent: WO 01/68607 (2001-09-01), None
patent: WO 01/68608 (2001-09-01), None
patent: WO 02/100833 (2002-12-01), None
patent: WO 03/051366 (2003-06-01), None
patent: WO 03/059913 (2003-07-01), None
patent: WO 03/062227 (2003-07-01), None
patent: WO 2004/000318 (2003-12-01), None
patent: WO 2004/009555 (2004-01-01), None
patent: WO 2004/024717 (2004-03-01), None
patent: WO 2004/084824 (2004-10-01), None
patent: WO 2004/085409 (2004-10-01), None
patent: WO 2005/003101 (2005-01-01), None
patent: WO 2006/071548 (2006-07-01), None
US 6,503,924, 01/2003, Azuma et al. (withdrawn)
Adachi et al., Studies on Pyrazines. I. The Syntheses of 2,3-Dihydroxypyrazines and Their Derivatices, J. Org. Chem., vol. 37(2):221-225, 1972.
Fukiage et al., Involvement of Phosphorylation of Myosin Phosphatase by ROCK in Trabecular Meshwork and Ciliary Muscle Contraction, Biochemical and Biophysical Research Communications, vol. 288:296-300, 2001.
Honjo et al., Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility, Investigative Ophthalmology & Visual Science, vol. 42(1):137-144, 2001.
Honjo et al., Effects of Protein Kinase Inhibitor, HAJ077, on Intraocular Pressure and Outflow Facility in Rabbit Eyes, Arch Ophthalmol., vol. 119:1171-1178, 2001.
Ishizaki et al., Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases, Molecular Pharmacology, vol. 57:976-983, 2000.
Loge et al., Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885, Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 17(6):381-390, 2002.
Loge et al., Synethesis and Pharmacological Study of Rho-Kinase Inhibitors: Pharmacomodulations on the Lead Compound Fasudil, Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 18(2):127-138, 2003.
Rao et al., Modulation of Aqueous Humor Outflow Facility by the Rho Kinase Specific Inhibitor Y-27632, Investigative Ophthalmology & Visual Science, vol. 42(5):1029-1037, 2001.
Sasaki et al., Novel and Specific Rho-Kinase Inhibitor, H1152P, Directed Against the Rho-Kinase Involved Pathway, Cell Biol. Mol. Lett, vol. 6(2B):506, 2001.
Sasaki et al., The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway, Pharmacology & Therapeutics, vol. 93:225-232, 2002.
Sato et al., Studies on Pyrazines. Part 33. Synthesis of 2,3-Diaminopyrazines via [1,2,5]Thiadiazolo[3,4-b] pyrazines, J. Chem Research, (S):250-251, 1997.
Sato et al., Studies on Pyrazines; Part 30: Synthesis of Aminopyrazines for Azidopyrazines, Synthesis, vol. 9:931-934, 1994.
Sato et al., Studies on Pyrazines. Part 27. A New Deoxidative Nucleophilic Substitution of Pyrazine N-Oxides; Synthesis of Azidopyrazines with Trimethylsilyl Azide, Journal Chem Society, vol. 7:885-888, 1994.
Sato et al., Studies on Pyrazines. 3. A Facile Synethic Method for 2,d-Diaminopyrazines, Journal Org. Chem., vol. 43(2):341-343, 1978.
Satoh et al., Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage, Life Sciences, vol. 69:1441-1453, 2001.
Sharif et al., Pharmacological and Molecular Biological (RT-PCR) Characterization of Functional TP Prostanoid Receptors in Immortalized Human Non-Pigmented Ciliary Epithelial Cells, Journal of Ocular Pharmacology and Therapeutics, vol. 18(2):141-162, 2002.
Sharif et al., Pharmacology of [3H]Prostaglandin E1[3H]Prostaglandin E2 and [3H]Prostaglandin F2a Binding to EP3 and FP Prostaglandin Receptor Binding . . . with Functional Data., Journal of Pharmacology and Experimental Therapeutics, vol. 286:1094-1102, 1998.
Sharif et al., Affinities, Selectivities, Potencies, and Intrinsic Activities of Natural and Synthetic Prostanoids Using Endogenous Receptors: Focus on DP Class Prostanoids, J of Pharmacology and Experimental Therapeutics, vol. 293(2):321-328, 2000.
Sharif et al., Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques, vol. 54:539-547, 2002.
Takami et al., Design and synthesis of Rho kinase inhibitors (I), Bioorganic & Medicinal Chemistry, vol. 12:2115-2137, 2004.
Thieme et al., Mediation of Calcium-Independent Contraction in Trabecular Meshwork through Protein Kinase C and Rho-A, Investigative Ophthalmology & Visual Science, vol. 41:4240-4246, 2000.
Tian et al., Effects of Topical H-7 on Outflow Facility, Intraocular Pressure, and Corneal Thickness in Monkeys, vol. 122:1171-1177, 2004.
Uehata et al., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension, Letters to Nature, vol. 389:990-994, 1997.
Waki et al., Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase, Current Eye Research, vol. 22(6):470-474, 2001.
Wettschureck et al., Rho/Rho-kinase mediated signaling in physiology and pathophysiology, Journal Molecular Medicine, vol. 80:629-638, 2002.
Database Registry, Jul. 23, 2006, XP002431871; retrieved from STN accession No. RN895237-47-5 abstract.
Database Registry, Jul. 23, 2006, XP002431872; retrieved from STN accession No. RN895237-46-4 abstract.
Database Registry, Jul. 23, 2006, XP002431873; retrieved from STN accession No. RN895237-29-3 abstract.
Rao et al., “Modulation of Aqueous Humor Outflow Facility by the rho Kinase-Specific Inhibitor Y-27632”, IOVS, vol. 42:1029-1037, 2001.
Chen Hwang-Hsing
Hellberg Mark R.
May Jesse A.
Rusinko Andrew
Sharif Najam A.
Alcon Research, Ltd.
Flanigan Mark E.
Weddington Kevin
LandOfFree
(Indazol-5-yl)-pyrazines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Indazol-5-yl)-pyrazines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Indazol-5-yl)-pyrazines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177594